Borghetti A, Moschese D, Cingolani A, et al. - Given the increasing popularity of two-drug antiretroviral regimens based on lamivudine plus either a protease inhibitor (PI) or dolutegravir in switch strategies, researchers sought to derive a predictive score for virological failure (VF). Data for a cohort of 587 virologically suppressed (HIV RNA < 37 HIV-1 RNA copies/mL), adult (≥ 18 years old) patients starting lamivudine plus either a boosted PI or dolutegravir was retrospectively analyzed. Thirty-five VFs occurred during a median of 2 years of follow-up time. The major predictors of VF in this cohort were the presence of at least one resistance-associated mutation (RAM), higher residual viraemia and African ethnicity. They assigned a score of 2 to non-B viral subtype, 3 to residual viraemia ≥ 20 copies/mL, ≥ 10 previous therapeutic lines and African ethnicity, 4 to baseline CD4 count < 200 cells/μL, and 7 to the presence of at least one RAM (excluding M184V).